Prognostic role of CA-125 in patients undergoing transcatheter aortic valve replacement: A systematic review and meta-analysis.

ABSTRACT: Transcatheter aortic valve replacement (TAVR) has become a widely used therapy for patients with severe aortic stenosis. Carbohydrate antigen 125 (CA-125) is a promising biomarker in some cardiovascular diseases. This systematic review aims to assess the prognostic role of CA-125 in patients undergoing TAVR. We searched electronic databases from inception to March 2023 to include cohort studies evaluating the association between preprocedural CA-125 levels and mortality or heart failure (HF) readmission at 12 months in patients undergoing TAVR. We pooled crude (cHR) and adjusted hazard ratios (aHR) with their 95% confidence interval (CI) using a random-effects model. The risk of bias was evaluated using the QUIPS tool. The certainty of the evidence was assessed using the GRADE approach. We

SUBMITTER: Diaz-Arocutipa C 

PROVIDER: S-EPMC10577531 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature